New CEO to advance VectorY’s ALS therapy VTx-002

VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer.

The company is advancing its lead therapy, VTx-002, targeting amyotrophic lateral sclerosis (ALS), while also expanding into the USA with a new office in Boston. Mr Scibetta succeeds founder and former CEO Sander van Deventer, who now takes on the role of president of R&D.

VTx-002, a vectorized antibody therapy targeting the TDP-43 protein, has shown promise in preclinical studies and recently received favorable feedback from the US Food and Drug Administration regarding its data package, manufacturing standards, and clinical trial design. The program is on track to enter the clinic by late 2025.